Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports.Check Now!

Home
report store
progressive supranuclear palsy psp epidemiology forecast

progressive-supranuclear-palsy-psp-epidemiology-forecast-report

SALE

Progressive supranuclear palsy (PSP) - Epidemiology Forecast-2034

Published Date : 2025

Pages : 80

Region : United States, Japan, EU4 & UK

SALE

Summary
TOC Table of Content
LOT
- Sample Request

progressive supranuclear palsy psp epidemiology forecast

DelveInsight’s "Progressive supranuclear palsy (PSP) - Epidemiology Forecast-2034" report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Progressive supranuclear palsy in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.

Geography Covered

• The United States

• EU5 (Germany, France, Italy, Spain and the United Kingdom)

• Japan

Study Period: 2017-2034

Progressive supranuclear palsy Disease Understanding

Progressive Supranuclear Palsy (PSP) is an adult onset, progressive, sporadic neurodegenerative disease and an important cause of atypical Parkinsonism. The classic syndrome of PSP (Richardson’s syndrome or RS) is characterized by postural instability and falls early in the disease course and by gaze dysfunction affecting the vertical eye movements more than the horizontal ones.

Progressive supranuclear palsy Epidemiology

The Progressive supranuclear palsy epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. The epidemiology data for Progressive supranuclear palsy are studied through all possible division to give a better understanding about the Disease scenario in 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Progressive supranuclear palsy Epidemiology Segmentation

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Prevalence of Progressive supranuclear palsy, Phenotype associated with Progressive supranuclear palsy, Gender specific Prevalence of Progressive supranuclear palsy, Comorbidities associated with Progressive supranuclear palsy) scenario of Progressive supranuclear palsy in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2034.

The DelveInsight report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

According to DelveInsight estimates, there were 98,498 cases of Progressive supranuclear palsy in 7MM in 2017.

Report Scope

• The report covers detailed overview of Progressive supranuclear palsy explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns

• The report provides the insight about the historical and forecasted patient pool of Progressive supranuclear palsy in 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan

• The Report assesses the disease risk and burden and highlights the unmet needs of the disease

• The Report helps to recognize the growth opportunities in the 7MM with respect to the patient population

• The report provides the segmentation of the disease epidemiology by prevalence of Progressive supranuclear palsy, phenotype associated with Progressive supranuclear palsy, gender specific prevalence of Progressive supranuclear palsy, comorbidities associated with Progressive supranuclear palsy

Key strengths

• 11 Years Forecast

• 7MM Coverage

• Epidemiology Segmentation

• Key Cross Competition

• Market Size by Therapies

• Drugs Uptake

Key assessments

• Pipeline Product Profiles

• Key Products and Key Players

• Market Drivers and Barriers

1 Key Insight

2 Executive Summary of Progressive Supranuclear Palsy

3 SWOT Analysis for Progressive Supranuclear Palsy

4 Progressive Supranuclear Palsy (PSP) Epidemiology Overview at a Glance

4.1 Epidemiology of Progressive Supranuclear Palsy (PSP) in 2017

4.2 Epidemiology of Progressive Supranuclear Palsy (PSP) in 2030

5 Disease Background and Overview: Progressive Supranuclear Palsy (PSP)

5.1 Introduction

5.2 Signs and symptoms

5.3 Phenotypes of Progressive Supranuclear Palsy

5.4 History

5.5 Associated risk factors

5.6 Genetics

5.7 Pathophysiology

5.8 PSP associated abnormalities

5.9 Clinical Presentation and Assessment

5.10 Clinical Diagnosis of Progressive Supranuclear Palsy: The Movement Disorder Society Criteria

5.11 PET Imaging as a Biomarker in Tauopathies

6 Epidemiology and Patient Population

6.1 Key Findings

6.2 7MM Total Prevalent Patient Population of Progressive Supranuclear Palsy [PSP]

7 Country Wise-Epidemiology of Progressive Supranuclear Palsy (PSP)

7.1 The United States

7.1.1 Assumptions and Rationale

7.1.2 Total Prevalent Patient Population of PSP in the United States

7.1.3 Phenotype associated with PSP in the United States

7.1.4 Gender specific Prevalence of PSP in the United States

7.1.5 Comorbidities associated with PSP in the United States

7.2 Europe

7.2.1 Assumptions and Rationale

7.2.2 Germany

7.2.2.1 Total Prevalent Patient Population of PSP in Germany

7.2.2.2 Phenotype associated with PSP in Germany

7.2.2.3 Gender specific Prevalence of PSP in Germany

7.2.2.4 Comorbidities associated with PSP in Germany

7.2.3 France

7.2.3.1 Total Prevalent Patient Population of PSP in France

7.2.3.2 Phenotype associated with PSP in France

7.2.3.3 Gender specific Prevalence of PSP in France

7.2.3.4 Comorbidities associated with PSP in France

7.2.4 Italy

7.2.4.1 Total Prevalent Patient Population of PSP in Italy

7.2.4.2 Phenotype associated with PSP in Italy

7.2.4.3 Gender specific Prevalence of PSP in Italy

7.2.4.4 Comorbidities associated with PSP in Italy

7.2.5 Spain

7.2.5.1 Total Prevalent Patient Population of PSP in Spain

7.2.5.2 Phenotype associated with PSP in Spain

7.2.5.3 Gender specific Prevalence of PSP in Spain

7.2.5.4 Comorbidities associated with PSP in Spain

7.2.6 The United Kingdom

7.2.6.1 Total Prevalent Patient Population of PSP in the United Kingdom

7.2.6.2 Phenotype associated with PSP in the United Kingdom

7.2.6.3 Gender specific Prevalence of PSP in the United Kingdom

7.2.6.4 Comorbidities associated with PSP in the United Kingdom

7.3 Japan

7.3.1 Assumptions and Rationale

7.3.2 Total Prevalent Patient Population of PSP in Japan

7.3.3 Phenotype associated with PSP in Japan

7.3.4 Gender specific Prevalence of PSP in Japan

7.3.5 Comorbidities associated with PSP in Japan

8 Treatment

8.1 Current symptomatic treatment

9 Unmet Needs

10 Appendix

10.1 Report Methodology

11 DelveInsight Capabilities

12 Disclaimer

13 About DelveInsight

List of Tables:

Table 1: Summary of Progressive Supranuclear Palsy (PSP) Market, Epidemiology, and Key Events (2017–2030)

Table 2: Core clinical features

Table 3: Supportive Features

Table 4: Diagnostic criteria for PSP

Table 5: Total Prevalent Patient Population of PSP in 7MM (2017–2030)

Table 6: Total Prevalent Population of PSP in the United States (2017–2030)

Table 7: Phenotype associated with PSP in the United States (2017–2030)

Table 8: Gender specific Prevalence of PSP in the United States (2017–2030)

Table 9: Comorbidities associated with PSP in the United States (2017–2030)

Table 10: Total Prevalent Population of PSP in Germany (2017–2030)

Table 11: Phenotype associated with PSP in Germany (2017–2030)

Table 12: Gender specific Prevalence of PSP in Germany (2017–2030)

Table 13: Comorbidities associated with PSP in Germany (2017–2030)

Table 14: Total Prevalent Population of PSP in France (2017–2030)

Table 15: Phenotype associated with PSP in France (2017–2030)

Table 16: Gender specific Prevalence of PSP in France (2017–2030)

Table 17: Comorbidities associated with PSP in France (2017–2030)

Table 18: Total Prevalent Population of PSP in Italy (2017–2030)

Table 19: Phenotype associated with PSP in Italy (2017–2030)

Table 20: Gender specific Prevalence of PSP in Italy (2017–2030)

Table 21: Comorbidities associated with PSP in Italy (2017–2030)

Table 22: Total Prevalent Population of PSP in Spain (2017–2030)

Table 23: Phenotype associated with PSP in Spain (2017–2030)

Table 24: Gender specific Prevalence of PSP in Spain (2017–2030)

Table 25: Comorbidities associated with PSP in Spain (2017–2030)

Table 26: Total Prevalent Population of PSP in the United Kingdom (2017–2030)

Table 27: Phenotype associated with PSP in the United Kingdom (2017–2030)

Table 28: Gender specific Prevalence of PSP in the United Kingdom (2017–2030)

Table 29: Comorbidities associated with PSP in the United Kingdom (2017–2030)

Table 30: Total Prevalent Population of PSP in Japan (2017–2030)

Table 31: Phenotype associated with PSP in Japan (2017–2030)

Table 32: Gender specific Prevalence of PSP in Japan (2017–2030)

Table 33: Comorbidities associated with PSP in Japan (2017–2030)

List of Figures:

Figure 1: SWOT Analysis

Figure 2: Tau isoforms and conformations

Figure 3: Tau hyperphosphorylation and aggregation

Figure 4: Total Prevalent Patient Population of PSP in 7MM (2017–2030)

Figure 5: Prevalence of PSP in the United States (2017–2030)

Figure 6: Phenotype associated with PSP in the United States (2017–2030)

Figure 7: Gender specific Prevalence of PSP in the United States (2017–2030)

Figure 8: Comorbidities associated with PSP in the United States (2017–2030)

Figure 9: Prevalence of PSP in Germany (2017–2030)

Figure 10: Phenotype associated with PSP in Germany (2017–2030)

Figure 11: Gender specific Prevalence of PSP in Germany (2017–2030)

Figure 12: Comorbidities associated with PSP in Germany (2017–2030)

Figure 13: Prevalence of PSP in France (2017–2030)

Figure 14: Phenotype associated with PSP in France (2017–2030)

Figure 15: Gender specific Prevalence of PSP in France (2017–2030)

Figure 16: Comorbidities associated with PSP in France (2017–2030)

Figure 17: Prevalence of PSP in Italy (2017–2030)

Figure 18: Phenotype associated with PSP in Italy (2017–2030)

Figure 19: Gender specific Prevalence of PSP in Italy (2017–2030)

Figure 20: Comorbidities associated with PSP in Italy (2017–2030)

Figure 21: Prevalence of PSP in Spain (2017–2030)

Figure 22: Phenotype associated with PSP in Spain (2017–2030)

Figure 23: Gender specific Prevalence of PSP in Spain (2017–2030)

Figure 24: Comorbidities associated with PSP in Spain (2017–2030)

Figure 25: Prevalence of PSP in the United Kingdom (2017–2030)

Figure 26: Phenotype associated with PSP in the United Kingdom (2017–2030)

Figure 27: Gender specific Prevalence of PSP in the United Kingdom (2017–2030)

Figure 28: Comorbidities associated with PSP in the United Kingdom (2017–2030)

Figure 29: Prevalence of PSP in Japan (2017–2030)

Figure 30: Phenotype associated with PSP in Japan (2017–2030)

Figure 31: Gender specific Prevalence of PSP in Japan (2017–2030)

Figure 32: Comorbidities associated with PSP in Japan (2017–2030)

Figure 33: Potential therapeutic targets for progressive supranuclear palsy

Figure 34: Potential therapeutic targets for progressive suparnuclear palsy

Figure 35: Unmet Needs of PSP

Tags:

License Type

Offer